Subcutaneous immunoglobulin (SCIg) typically takes about 4 weeks to reach its full therapeutic effect, compared to 1 to 2 weeks for the intravenous (IVIg) form. This slower onset is a direct result of how the drug enters your bloodstream: instead of going straight into a vein, it’s injected under the skin and absorbed gradually over 48 to 72 hours. If you’re switching from IVIg to SCIg, though, the transition can be managed so you don’t experience a gap in protection.
Why SCIg Works More Slowly Than IVIg
The key difference comes down to how your body absorbs the immunoglobulin. IVIg delivers a large dose directly into the bloodstream, where it can raise antibody levels within minutes to levels up to four times higher than before the infusion. That spike translates to noticeable improvement, particularly in conditions like CIDP (chronic inflammatory demyelinating polyneuropathy), where patients often feel stronger within days.
SCIg takes a different route. The immunoglobulin is deposited into the fatty tissue under your skin, where it slowly diffuses into the bloodstream over two to three days. Peak blood levels after an SCIg dose are only about 60% of what you’d see after the same IVIg dose. On top of that, some of the immunoglobulin binds to tissue or breaks down before it ever reaches the blood, which is why SCIg doses are typically increased by 30 to 50% compared to the equivalent IVIg dose.
The trade-off is stability. IVIg creates a rollercoaster pattern: antibody levels spike right after infusion, then steadily drop over three to four weeks until the next dose. Many patients feel this as a “wear-off” effect toward the end of each cycle, with symptoms returning before the next infusion is due. SCIg, given weekly or twice weekly in smaller amounts, produces much more consistent antibody levels. The peaks are lower, but so are the troughs, which means more sustained benefit day to day and fewer side effects from those dramatic spikes.
What the 4-Week Timeline Looks Like
If you’re starting SCIg without any prior immunoglobulin therapy, expect about four weeks before your antibody levels reach a steady therapeutic range. During the first couple of weeks, each dose is building on the last. Because the body takes two to three days to fully absorb each infusion and antibody levels don’t fluctuate as dramatically, it takes several weekly doses to reach what’s called a steady state, where the amount going in roughly matches the amount being used up or cleared.
For patients with neurological conditions like CIDP, this means you may not notice meaningful improvements in muscle strength or sensation during those first few weeks. In contrast, IVIg can produce noticeable strength gains within the first one to two weeks. This is worth knowing so you don’t assume SCIg isn’t working just because results aren’t immediate.
Switching From IVIg to SCIg
Most people starting SCIg are actually transitioning from IVIg rather than beginning immunoglobulin therapy for the first time. The timing of your switch matters because you want to avoid a dip in antibody levels that could let symptoms return.
The standard approach is to start your first SCIg dose within one week of your last IVIg infusion. This keeps your antibody levels from dropping too low during the transition. There are two common ways to do this:
- Immediate switch: You receive your full weekly SCIg dose one week after your last IVIg infusion. This works well if the volume of your dose is manageable for a single injection session.
- Gradual transition: On the same day as your last IVIg dose, you start SCIg at 25% of your target weekly dose. The following week, you go to 50%. By week three, you’re at the full dose. This approach is preferred if your dose volume is high or if your doctor wants to ease you into the process.
For patients using a product that includes an enzyme to help absorption (allowing larger volumes less frequently), the schedule differs slightly. You might start your SCIg when your next IVIg dose would have been due, or about two weeks after your last IVIg infusion with a gradual dose increase over the first few sessions.
Neither approach involves a special “loading dose.” The goal is simply to time the switch so your existing IVIg levels carry you through until the SCIg reaches steady state.
What Happens if Symptoms Return
In studies of CIDP patients on SCIg maintenance therapy, some patients who were placed on lower doses experienced relapses. When their dose was increased back to the standard level of 0.4 grams per kilogram of body weight, 92% recovered successfully. Recovery in these cases was defined as returning to their previous level of function, and patients were expected to recover within about four weeks of restarting the higher dose.
This four-week window reinforces the general timeline: whether you’re starting fresh, switching, or recovering from a dose adjustment, about a month is the benchmark for SCIg to reach full effectiveness.
Adjusting to Injection Site Reactions
While you’re waiting for SCIg to reach its full effect, you’ll also be adjusting to the infusion process itself. Most people experience local reactions at the injection site, especially in the early months. These typically include an egg-sized lump of swelling, redness, and firmness at the spot where the needle went in. These reactions are normal and usually resolve by the next day.
The good news is that your body adapts. Most people notice a significant decrease in these local reactions after about 8 to 10 weeks. The skin and tissue at your infusion sites essentially become more accustomed to the process. Rotating injection sites and using proper technique, which your healthcare team will train you on, can help minimize discomfort during this adjustment period.
The Long-Term Payoff
The slower onset of SCIg can feel frustrating compared to the more immediate response many patients experience with IVIg. But the steady-state levels that SCIg provides offer a real advantage over time. Without the peaks and troughs of monthly IVIg infusions, many patients report feeling more consistent from day to day. There’s no end-of-cycle fatigue or symptom flare while waiting for the next infusion. The side effects that come with high peak levels, such as headaches, nausea, and fatigue, are also less common with SCIg because the antibody levels stay in a narrower, more moderate range.
For most patients, the practical answer is straightforward: give SCIg about four weeks to reach full effectiveness, plan the switch carefully if you’re coming from IVIg, and expect the injection site discomfort to ease up after two to three months.